Repligen Corp.

Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the process of manufacturing biological drugs. The company's bioprocessing business is comprised of: Chromatography, which includes products used in downstream purification, development, manufacturing and quality control of biological drugs; Filtration, which includes XCell Alternating Tangential Flow systems that are used in upstream perfusion cell culture processing; Process Analytics, which complements and supports its Filtration, Chromatography and Proteins franchises; and OEM products, which are represented by its Protein A affinity ligands and cell culture growth factor products
  • TickerRGEN
  • ISINUS7599161095
  • ExchangeNASDAQ Stock Market
  • SectorHealth Care Equipment & Services
  • CountryUnited States
RGEN REPLIGEN CORP. (Health Care)

Due to a more favourable environment, REPLIGEN slightly increases to N...

REPLIGEN (US), a company active in the Medical Equipment industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as moderately risky. At the fundamental level, theScreener confirms the rating of 1 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Neutral even if it remains under pressure. As of the analysis date June 8, 2021, the closing price was USD 182.49 and its target price was estimated at USD 143.78.

 PRESS RELEASE
RGEN REPLIGEN CORP. (Health Care)

Repligen Corporation to Present at Upcoming Investor Conferences

Repligen Corporation to Present at Upcoming Investor Conferences WALTHAM, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at two upcoming investor conferences. William Blair 41st Annual Growth Stock conference being held June 1 - 3.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, June 1, at 1:40 p.m. EST.  Jefferies Virtual Healthcare Conference being held June 1 - 3.   Tony J. Hunt, Presid...

RGEN REPLIGEN CORP. (Health Care)

Repligen Corp: 1 director

A director at Repligen Corp sold 22,267 shares at 171.406USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board...

 PRESS RELEASE
RGEN REPLIGEN CORP. (Health Care)

Repligen to Report First Quarter 2021 Financial Results

Repligen to Report First Quarter 2021 Financial Results Webcast and Conference Call to Be Held Tuesday, May 4, 2021 at 8:30 a.m. EDT WALTHAM, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2021 financial results on Tuesday, May 4, 2021. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three-month reporting period ended March 31, 2021.The conference call will be accessible by d...

 PRESS RELEASE
RGEN REPLIGEN CORP. (Health Care)

Repligen Corporation to Present at Barclays Global Healthcare Conferen...

Repligen Corporation to Present at Barclays Global Healthcare Conference WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chief Financial Officer, will participate in a fireside chat on Wednesday, March 10, at 1:50 p.m. EST. A live webcast of the discussion will be accessible through the  section of the Company’s website, and will be available for repla...

 PRESS RELEASE
RGEN REPLIGEN CORP. (Health Care)

Repligen Corporation to Present at Upcoming Investor Conferences

Repligen Corporation to Present at Upcoming Investor Conferences WALTHAM, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at two upcoming investor conferences. William Blair 41st Annual Growth Stock conference being held June 1 - 3.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, June 1, at 1:40 p.m. EST.  Jefferies Virtual Healthcare Conference being held June 1 - 3.   Tony J. Hunt, Presid...

RGEN REPLIGEN CORP. (Health Care)

Repligen Corp: 1 director

A director at Repligen Corp sold 22,267 shares at 171.406USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board...

 PRESS RELEASE
RGEN REPLIGEN CORP. (Health Care)

Repligen to Report First Quarter 2021 Financial Results

Repligen to Report First Quarter 2021 Financial Results Webcast and Conference Call to Be Held Tuesday, May 4, 2021 at 8:30 a.m. EDT WALTHAM, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2021 financial results on Tuesday, May 4, 2021. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three-month reporting period ended March 31, 2021.The conference call will be accessible by d...

 PRESS RELEASE
RGEN REPLIGEN CORP. (Health Care)

Repligen Corporation to Present at Barclays Global Healthcare Conferen...

Repligen Corporation to Present at Barclays Global Healthcare Conference WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chief Financial Officer, will participate in a fireside chat on Wednesday, March 10, at 1:50 p.m. EST. A live webcast of the discussion will be accessible through the  section of the Company’s website, and will be available for repla...

 PRESS RELEASE
RGEN REPLIGEN CORP. (Health Care)

Repligen Reports Fourth Quarter and Full Year 2020 Financial Results

Repligen Reports Fourth Quarter and Full Year 2020 Financial Results Reports quarterly revenue of $108.6 million, representing 56% year-over-year growth, and annual revenue of $366.3 million represents 36% year-over-year growthOrganic revenue growth was 47% for the fourth quarter and 29% for the year 2020 WALTHAM, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2020. Provided in this press release are financial highligh...

RGEN REPLIGEN CORP. (Health Care)

Due to a more favourable environment, REPLIGEN slightly increases to N...

REPLIGEN (US), a company active in the Medical Equipment industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as moderately risky. At the fundamental level, theScreener confirms the rating of 1 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Neutral even if it remains under pressure. As of the analysis date June 8, 2021, the closing price was USD 182.49 and its target price was estimated at USD 143.78.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch